培美曲塞治疗老年晚期肺腺癌的临床效果  

Clinical effect of Pemetrexed in the treatment of elderly patients with advanced lung adenocarcinoma

作　　者：冯丽娟 谢建立[2] 区雅影 陈倩瑜 花雪娇 FENG Li-juan;XIE Jian-li;OU Ya-ying;CHEN Qian-yu;HUA Xue-jiao(Department of Pharmacy,Beijiao Hospital of Shunde District in Foshan City,Guangdong Province,Foshan 528311,China;Department of Oncology,People′s Hospital of Gaoming District in Foshan City,Guangdong Province,Foshan 528500,China)

机构地区：[1]广东省佛山市顺德区北滘医院药剂科,广东佛山528311 [2]广东省佛山市高明区人民医院肿瘤科,广东佛山528500

出　　处：《中国当代医药》2019年第19期173-176,共4页China Modern Medicine

摘　　要：目的探讨培美曲塞和多西他赛治疗老年晚期肺腺癌的临床效果。方法选取2015年1月~2017年12月佛山市高明区人民医院收治的66例老年肺腺癌患者作为研究对象,按照患者化疗方案的不同将其分为观察组和对照组,每组各33例。观察组采用培美曲塞进行化疗,对照组采用多西他赛进行化疗。比较两组患者的近期疗效、肿瘤控制及不良反应发生情况。结果两组患者的治疗总有效率比较,差异无统计学意义(P>0.05),两组患者的肿瘤控制率比较,差异无统计学意义(P>0.05);观察期间,观察组患者的胃肠道反应发生率(24.24%)和肝肾损伤发生率(9.09%)低于对照组(48.48%,30.30%),差异有统计学意义(P<0.05);两组患者的骨髓抑制、神经毒性发生率比较,差异无统计学意义(P>0.05)。结论培美曲塞治疗老年晚期肺腺癌的临床效果与多西他赛大致相当,但其不良反应发生率更低,安全性更好。Objective To explore the clinical effects of Pemetrexed and Docetaxel in the treatment of elderly patients with advanced lung adenocarcinoma. Methods A total of 66 patients with lung adenocarcinoma admitted to People′s Hospital of Gaoming District in Foshan City from January 2015 to December 2017 were selected as study subjects. According to the different chemotherapy regimens, they were divided into the observation group and the control group, with 33 cases in each group. The observation group received chemotherapy with Pemetrexed, while the control group received chemotherapy with Docetaxel. The recent efficacy, tumor control status, and adverse reactions were compared between the two groups. Results There was no significant difference in the total effectiveness rate between the two groups (P>0.05). There was no significant difference in the tumor control rate between the two groups (P>0.05). During the observation period, the incidence of gastrointestinal reactions (24.24%) and liver and kidney injury (9.09%) in the observation group were lower than those of the control group (48.48%, 30.30%), the differences were statistically significant (P<0.05). There was no significant difference between the two groups in the incidence of bone marrow inhibition and neurotoxicity (P>0.05). Conclusion The effect of Pemetrexed in the treatment of elderly patients with advanced lung adenocarcinoma is tantamount to that of Docetaxel, but with lower adverse reactions and better safety.

关 键 词：晚期肺腺癌 培美曲塞 多西他赛 疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]